The U.S. Food and Drug Administration approved the oral drug daraxonrasib, branded as Rasonque, for advanced pancreatic cancer on Aug. 26, 2026 [2].
This approval marks a significant shift in oncology because it provides a targeted therapy for a specific genetic driver of one of the deadliest forms of cancer. For patients with late-stage disease who have not responded to existing therapies, this drug offers a new mechanism of action to slow disease progression.
Developed by Revolution Medicines, daraxonrasib is a first-of-its-kind oral therapy designed to target KRAS mutations [1]. These mutations are known to drive the growth and spread of pancreatic cancer cells. By inhibiting this specific protein, the drug aims to stop the signaling pathways that allow tumors to thrive [4].
Clinical data showed that the drug doubled survival time compared with chemotherapy alone in trial participants [1]. This result represents a substantial increase in life expectancy for a patient population that typically faces very poor prognoses with standard care.
The FDA granted the drug expedited approval to ensure faster access for those with limited treatment options [3]. The agency's decision focuses on the drug's ability to address an unmet medical need in the treatment of advanced pancreatic cancer [4].
Because the treatment is administered orally, it may reduce the burden on patients who otherwise rely on intravenous infusions. This shift in delivery method, combined with the targeted nature of the drug, distinguishes Rasonque from traditional cytotoxic chemotherapy.
Revolution Medicines developed the therapy to specifically address the KRAS gene mutation, which is a hallmark of the majority of pancreatic cancer cases [4]. The drug is now available for use in the U.S. following the agency's decision in Washington, D.C. [2].
“The drug doubled survival time compared with chemotherapy alone in trial participants.”
The approval of daraxonrasib signals a move toward precision medicine in pancreatic cancer treatment. By targeting the KRAS mutation rather than using broad-spectrum chemotherapy, clinicians can now treat the genetic driver of the tumor. This transition from general to targeted therapy typically results in higher efficacy and potentially fewer systemic side effects, providing a critical lifeline for patients with advanced-stage disease.
